Severe tophaceous gout. Characterization of low socioeconomic level patients from México

Clinical and Experimental Rheumatology

Volumn 24, Issue 3, 2006, Pages 233-238

  Vázquez Mellado, Janitzia ^a   Cruz, Jorge ^a   Guzmán, Silvia ^a   Casasola Vargas, Julio ^a   Lino, Leticia ^a   Burgos Vargas, Rubén ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Glucocorticoids; Gout; Tophaceous gout; Tophi; Uric acid

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; COLCHICINE; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; URIC ACID;

ACADEMIC ACHIEVEMENT; ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FREQUENCY ANALYSIS; GOUT; HUMAN; KIDNEY DYSFUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MEXICO; MORTALITY; OBESITY; ONSET AGE; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE; SOCIAL STATUS; SOCIOECONOMICS; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL BLEEDING; URBAN AREA; URIC ACID URINE LEVEL;

ADULT; AGE OF ONSET; COMORBIDITY; CROSS-CULTURAL COMPARISON; FEMALE; GLUCOCORTICOIDS; GOUT; HEALTH STATUS; HUMANS; KIDNEY DISEASES; MALE; MEXICO; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOCIAL CLASS; SOCIOECONOMIC FACTORS;

EID: 33746657536     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. CARDIEL MH, ROJAS-SERRANO J: Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 2002; 20: 617-24.
2. MIKULS TR, MacLEAN CH, OLIVIERI J et al.: Quality of care indicators for gout management. Arthritis Rheum 2004; 50: 937-43.
3. RIEDEL AA, NELSON M, JOSEPH-RIDGE N, WALLACE K, MacDONALD P, BECKER M: Compliance with allopurinol therapy among managed care enrollees with gout: A retrospective analysis of administrative claims. J Rheumatol 2004; 31: 1575-81.
4. PAL B, FOXALL M, DYSART T, CAREY F, WHITTAKER M: How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000; 19: 21-5.
5. DARMAWAN J, RASKER JJ, NURALIM H: The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years. J Rheumatol 2003; 30: 2437-43.
6. WALLACE KL, RIEDEL AA, JOSPH-RIDGE N, WORTMANN R: Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004; 31: 1582-7.
7. O'DUFFY JD, HUNDER GG, KELLEY PJ: Decreasing prevalence of tophaceous gout. Mayo Clin Proc 1975; 50: 227.
8. GRAHAME R, SCOTT J: Clinical survey of 354 patients with gout. Ann Rheum Dis 1970; 29: 461-8.
9. BRONFMAN M, GUISCAFRE H, CASTRO V, CASTRO R, GUTIÉRREZ G: La medición de la desigualdad: Una estrategia metodológica, Análisis de las características socioeconómicas de la muestra. Arch Invest Med 1988; 19: 351-60.
10. The Expert Commitee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Commitee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1999; (Suppl. 22): 4-19.
11. VÁZQUEZ-MELLADO J, CUAN A, MAGAÑA M et al.: Intradermal tophi in gout: A case-control study. J Rheumatol 1999; 26: 136-40.
12. CARDIEL MH, ABELLO BANFI, RUÍZ MERCADO R, ALARCÓN-SEGOVIA D: How to measure health status in rheumatoid arthritis in non-English speaking patient: Validation of a Spanish version of the Helat Assesment Questionnaire Disability index (Spanish HAQ-Di). Clin Exp Rheumatol 1994; 11: 117-21.
13. VÁZQUEZ-MELLADO J, MEOÑO MORALES E, PACHECO-TENA C, BURGOS VARGAS R: Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001; 60: 981-3.
14. CHANG SJ, KO YC, WANG TN, CHANG FT, CINKOTAI FF, CHEN CJ: High prevalence of gout and related risk factors in Taiwan's aborigines. J Rheumatol 1997; 24: 1364-9.
15. CHANG HY, PAN WH, YEH WT, TSAI KS: Hyperuricemia and gout in Taiwan: Results from the Nutritional and Health Survey in Taiwan. J Rheumatol 2001; 28: 1640-6.
16. CHEN SY, CHEN CL, SHEN ML, KAMATANI N: Trends in the manifestations of gout in Taiwan. Rheumatology 2003; 42: 1529-33.
17. CHOU CT, LAI JS: The epidemiology of hyperuricemia and gout in Taiwan aborigines. Br J Rheumatol 1998; 37: 258-62.
18. YU KH, LUO SF: Younger age at onset of gout in Taiwan. Rheumatology 2003; 42: 166-70.
19. ZENG Q, WANG Q, CHEN R, XIAO Z, HUANG S, XU J: Primary gout in Shamtou: a clinical and epidemiological study. Chin Med J 2003; 116: 66-9.
20. ALEGRÍA HERNANDEZ A, HERNANDEZ PAZ R: Artritis gotosa. Características clínicas. (abstract) Rev Mex Reumatol 1989; 4: 102.
21. BORI G: Principales enfermedades reumáticas en México. Aspectos espidemiológicos e impacto socioeconómico. Rev Mex Reumatol 2000; 15; 183-201.
22. OROZCO-ALCALA JJ, GUITIÉRREZ-UREÑA S: Curso y evolución de 300 casos de gota primaria (abstract). Rev Mex Reumatol 1992; 7: 33.
23. ROBLES GIL J, ARMAS C: Algunos aspectos epidemiológicos de la hiperuricemia y gota en México: prevalencia y factores de riesgo cardiovascular. Arch Inst Cardiol Mex 1978; 48: 1121-41.
24. SÁMANO G. GOTA: Estudio descriptivo en el Estado de Sonora. Rev Mex Reumatol 1998; 13: 172-5.
25. CASSIM B, MOODY GM, DEENADAYALU VK, HAMMOND MG: Gout in black South Africans: a clinical and genetic study. Ann Rheum Dis 1994; 53: 759-62
26. CARDONA F, TINAHONES FJ, COLLANTES E, ESCUDERO A, GARCÍA FUENTES E, SORIGUER F: Contribution of polymorphism in the apolipoprotein AI-CIII-AIV cluster to hyperlipidemia in patients with gout. Ann Rheum Dis 2005; 64: 85-8.
27. HONG YS, LEE MJ, KIM KH et al.: The C677 mutation in Methylene tetrahydrofolate reductase gene: Correlation with uric acid and cardiovascular risk factos in elderly Korean men. J Korean Med Sci 2004; 19: 209-13.
28. LO SF, HUAN CM, TSAI CH, CHEN ML, TSAI J: "Interlekukin-1 receptor antagonist gene polymorphism in Taiwanese patients with gout. Clin Exp Rheumatol 2005; 23: 85-8.
29. WILK JB, DJOUSSE L, BORECKI I et al.: Segregation analysis of serum uric acid in the NHLBI Family Heart Study. Human Genet 2000; 106: 355-9.
30. RUNDLES RW, METZ EN, SILBERMAN HR: Allopurinol in the treatment of gout. Ann Intern Med 1966; 64: 229-58.
31. DARMAWAN J, VALKENBURG HA, MUIRDEN KD, WIGLEY RD: The epidemiology of gout and hyperuricemia in a rural population of Java. J Rheumatol 1992; 19: 1595-9.
32. HALL A, BARRY P, DAWBER T, MCNAMARA P: Epidemiology of Gout and Hyperuricemia. Am J Med 1967; 42: 27-37.
33. HARRIS CM, LLOYD DCEF, LEWIS J: The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995; 48: 1153-8.
34. HOCHBERG MC, THOMAS J, THOMAS J, MEAD L, LEVINE DM, KLAG MJ: Racial differences in the incidence of gout. Arthritis Rheum 1995; 38: 628-32.
35. KLEMP P, STANSFIELD SA, CASTLE B, ROBERTSON MC: Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56: 22-6.
36. LENANNCE G, ROSE B, ISDALE I: Gout in Maori. Ann Rheum Dis 1960; 19: 120-5.
37. MIJIYAWA M, ONIANKITAN O: Risk factors for gout in Togolese patients. Joint Bone Spine 2000; 67: 441-5.
38. ROUBENOFF R, KLAG MJ, MEAD LA, LIANG KY, SEIDLER AJ, HOCHBERG MC: Incidence and risk factors for gout in white men. JAMA 1991; 266: 3004-7.
39. BERGER L, YÜ TF: Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. American Journal of Medicine 1975; 59: 605-13.
40. TARNG DC, LIN HY, SHYONG ML et al.: Renal function in gout patients. American Journal of Nephrology 1995; 15: 31-7.
41. ISEKI K, OSHIRO S, TOZAWA M et al.: Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertension Research 2001; 24: 691-7.
42. KANG DH, NAKAGAWA T, FENG L et al.: A role for uric acid in the progression of renal disease. Journal of the American Society of Nephrology 2002; 13: 2888-97.
43. GUZMÁN S, FARIAS P, CORTÉS M, HERNÁNDEZ AVILA M, BURGOS VARGAS R, VÁZQUEZ-MELLADO J: Bone lead measurement by X-ray fluorescence (XRF) and its relationship with nephropathy in gout. Arthritis and Rheum 1999; 42(Suppl.): S159.
44. HERNÁNDEZ AVILA M, SMITH D, MENESES F, SANIN LH, HU H: The influence of bone and blood lead on plasma lead levels in enviromentally exposed adults. Environ Health Perspect 1998: 106: 473-7.
45. GERTNER E, MARKSHALL PS, DILANDRINOS D, POTEK AS, SMITH TM: Complications resulting from the use of Chinese herbal medications containing undeclared prescription drugs. Arthritis Rheum 1995; 38: 614-7.
46. GOLDMAN JA: Chinese herbal medicine: camouflaged prescription antinflammatory drugs, costicosteroids and lead. Arthritis Rheum 1991; 34: 1207.
47. KRAPF R: Development of Cushing's syndrome after use of a herbal remedy. Lancet 2002; 360: 1884.
48. RULL M, CLAYBURNE G, SIECK M, SCHUMACHER HR: Intra-articular corticosteroid preparations: different characteristics and their effect during inflammation induced by monosodium urate crystals in the rat subcutaneous air pouch. Rheumatology 2003; 42: 1093-100.
49. VÁZQUEZ-MELLADO J, GARCÍA-GARCÍA C, GUZMÁN-VÁZQUEZ S et al.: Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol 2004; 10: 105-9.